Recruiting NA INTERVENTIONAL 1-arm NCT04838899

Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

Stereotactic Ablative Radiotherapy for Oligoprogressive Metastatic Castration-Resistant Prostate Cancer During Abiraterone Therapy

Sponsor: Sunnybrook Health Sciences Centre

Conditions Castration-Resistant Prostate Cancer Oligoprogressive

Interventions Stereotactic Body Radiation Therapy (SABR)

Updated 4 times since 2021 Last updated: Apr 10, 2024 Started: Jul 16, 2016 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Castration-Resistant Prostate Cancer and Oligoprogressive, this trial is actively recruiting participants. The trial is conducted by Sunnybrook Health Sciences Centre and has accumulated 4 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
May 2024 — Jul 2024 [monthly]

Recruiting NA
May 2021 — May 2024 [monthly]

Recruiting NA

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sunnybrook Health Sciences Centre

Data source: Sunnybrook Health Sciences Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada